Systemically administered RNAi molecule sensitizes malignant pleural mesothelioma cells to pemetrexed therapy

Systemically administered RNAi molecule sensitizes malignant pleural mesothelioma cells to pemetrexed therapy

Pemetrexed (PMX) is a key drug for the treatment of malignant pleural mesothelioma (MPM). However, its therapeutic efficacy is cruelly restricted in many clinical settings by the over-expression of thymidylate synthase (TS) gene. Recently, we emphasi...

Close